News About: Pharm. Industry
Dong-A to face tough challenge next year
The race for the generic drug market is set to be in full force in 2009.
The drug recently at the center of attention is the best-selling Stillen, a gastric membrane protector that will generate about 80 billion in...
Wyeth Korea accepts pay deal
Union members of Wyeth Korea agreed to accept a pay deal agreement on December 23 that had been struck between union leaders and management for 57 days.
Roughly 70 percent of union members voted for the 9.3 percent...
Health Insurance to cover Elaprase and Naglazyme
Those who have suffered from Mucopolysaccharidosis II (MPS II) and Mucopolysaccharidosis VI (MPS VI) will be covered by health insurance, the Ministry of Health, Welfare and Family Affairs said on December 22.
Elap...
CoaguChek system should be covered by health insurance
The national health insurance should cover Roche Diagnostics CoaguCheck system for patients on oral anticoagulant treatment, since it offers a simple, fast, and convenient way of directly monitoring their INR results,...
Huons’s smoking cessation aid debuts in domestic market
Nicopil gum, a new smoking cessation aid of Huons Co., made its debut in the domestic market valued at 20 billion won, the company said on December 23.
The sugar-free gum can give smokers confidence that they could...
AZK to lower Crestor price voluntarily
The Health Insurance Review and Assessment Service said on December 19 that it has finalized the assessment of economic effectiveness over Crestor, cholesterol-lowering drug to treat the clogging of arteries, followin...
SK Chemicals conducts organization reshuffleSK Chemicals has reshuffled its organization into two business units – chemical business and life sciences to develop new growth engines, it was announced on December 19.
The...
|
Kwangdong to introduce new rheumatoid arthritis treatment
Kwangdong Pharm has announced that it has signed an exclusive license agreement with Israel based Can-Fite BioPharma Ltd. to develop and commercialize the drug CF101 for the treatment of rheumatoid arthritis in Korea....
Merck to offer scholarship to Koreans
Merck Ltd, the Korean subsidiary of Merck KGaA, signed a memorandum of understanding on December 18 with College of Medicine, Seoul National University to provide its scholarship to the college.
It is proposed for ...
Dong-A’s Stillen to be exposed to fiercer competition
The homegrown drug in Korea will not be as stale as before with a growing number of pharmaceutical companies poising to enter a 70 billion Stillen market.
More than 20 pharmaceutical manufacturers are expected to ...
